Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $381 from $363 and keeps an Overweight rating on the shares. After having conducted a proprietary survey of U.S. physicians who treat Alzheimer’s, the firm raises its estimates for both Eli Lilly (LLY) and Biogen and sees Leqembi 2024 consensus estimates as “achievable,” the analyst tells investors. Given full approval of Leqembi in July and expected FDA approval of donanemab in Q4, the firm expects a modest initial launch, followed by an inflection in prescribing over the next 12 months for the Alzheimer’s medicines in the U.S. as centers develop the necessary protocols for prescribing, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biogen Appoints Jane Grogan as Head of Research
- Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind
- Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet Partnership
- Biogen price target raised to $357 from $354 at RBC Capital
- Novartis’ (NYSE:NVS) Sandoz Bags FDA Approval for Multiple Sclerosis Treatment